Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy

被引：16

作者：

Bonilla-Abadia, F. ^{[1
]}

Betancurt, J. F. ^{[2
]}

Pineda, J. C. ^{[2
]}

Velez, J. D. ^{[3
]}

Tobon, G. J. ^{[1
]}

Canas, C. A. ^{[1
]}

机构：

[1] ICESI Univ, Rheumatol Unit, Fdn Valle Lili, Cali, Colombia

[2] ICESI Univ, Internal Med Unit, Fdn Valle Lili, Cali, Colombia

[3] ICESI Univ, Infect Dis Unit, Fdn Valle Lili, Cali, Colombia

来源：

CLINICAL RHEUMATOLOGY | 2014年 / 33卷 / 03期

关键词：

Pneumonia; Pneumocystis; Pneumocystis jirovecii; Rituximab; Systemic; Systemic lupus erythematosus; RHEUMATOID-ARTHRITIS; CARINII; INFECTION; LYMPHOMA; DISEASE; CELLS;

D O I：

10.1007/s10067-013-2475-0

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.

引用

页码：415 / 418

页数：4

共 19 条

[1]

Bonilla-Abadia F, 2012, CASE REP RHEUMATOL, V2012

[2]

Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy [J].

Castagnola, E ;

Dallorso, S ;

Faraci, M ;

Morreale, G ;

Di Martino, D ;

Cristina, E ;

Scarso, L ;

Lanino, E .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2003, 12 (01) :9-10

[3]

CHESNUT RW, 1982, ADV IMMUNOL, V39, P51

[4]

The pathogenesis of systemic lupus erythematosus-an update [J].

Choi, Jinyoung ;

Kim, Sang Taek ;

Craft, Joe .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (06) :651-657

[5]

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up [J].

Czuczman, MS ;

Weaver, R ;

Alkuzweny, B ;

Berlfein, J ;

Grillo-López, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4711-4716

[6]

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis [J].

Dass, Shouvik ;

Vital, Edward M. ;

Emery, Paul .

EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (18) :2559-2570

[7]

Ferreira S, 2009, ACTA REUMATOL PORT, V34, P200

[8]

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients [J].

Garcia-Carrasco, M. ;

Mendoza-Pinto, C. ;

Sandoval-Cruz, M. ;

Soto-Vega, E. ;

Beltran-Castillo, A. ;

Jimenez-Hernandez, M. ;

Graillet, D. ;

Gonzalez, L. ;

Rojas-Rodriguez, J. ;

Pineda-Almazana, A. ;

Zamudio-Huerta, L. ;

Lopez-Colombo, A. .

LUPUS, 2010, 19 (02) :213-219

[9]

Rituximab-Associated Infections [J].

Gea-Banacloche, Juan C. .

SEMINARS IN HEMATOLOGY, 2010, 47 (02) :187-198

[10]

Gigliotti Francis, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010203

← 1 2 →